Search results
Showing 1 to 15 of 83 results for atezolizumab
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults who have not had previous systemic treatment.
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)
Evidence-based recommendations on atezolizumab (Tecentriq) for adjuvant treatment of resected non-small-cell lung cancer in adults.
Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults.
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell lung cancer in adults.
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable.
Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults.
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
NICE is unable to make a recommendation on atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer, because Roche did not provide an evidence submission.
Show all sections
Sections for TA618
In development [GID-TA11616] Expected publication date: 23 July 2025
Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)
Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.